|
Patent landscape, scope, and claims: |
Scope and Claim Construction for US Patent 6,239,113 (Azalide-Aqueous Polymeric Suspension for Topical Eye Treatment): What’s Covered, What’s Not, and the Practical Patent Landscape in the US
US 6,239,113 is a US utility patent claiming a specific topical ophthalmic process: applying an aqueous polymeric suspension containing an azalide antibiotic at defined concentration ranges, using a polymeric suspending agent defined by class and (in dependent claims) by chemistry, composition, particle properties, and specific azalide species (including azithromycin dihydrate). The claims are tightly framed around (i) formulation composition in an aqueous vehicle, (ii) polymer suspension mechanics using water-swellable, water-insoluble crosslinked carboxy-vinyl polymers, and (iii) optional refinements that narrow to acrylic-acid-rich crosslinked polymers, specific crosslinkers, polycarbophil, target suspending agent concentration, monodisperse particles, and azithromycin/azithromycin dihydrate.
The actionable takeaway: design-around risk is highest if a challenger maintains the same active (azithromycin or close azalide substitutes) and keeps the same suspension polymer class (water-swellable, water-insoluble crosslinked carboxy-vinyl polymers with acrylic acid monomer dominance), especially at the claimed concentration bands and with similar particle-size distribution/monodispersity.
What exactly does US Patent 6,239,113 claim for topical eye treatment?
Claim 1: Core process definition (aqueous polymeric suspension + azalide concentration band)
Independent claim 1 defines a “process for treating an eye” by topically applying a specific composition. The composition limitations control infringement more than the word “process.”
Claim 1 elements
- Method: “process for treating an eye” via topical application.
- Vehicle type: aqueous polymeric suspension.
- Azalide antibiotic: included in 0.01% to 1.0% (w/w implied by typical composition claim practice) of an azalide antibiotic.
- Polymeric suspending agent: present at 0.1% to 10%.
Practical scope
- The claim is broad on:
- The exact eye indication (it says “treating an eye” without limiting disease).
- The exact azalide species beyond the class “azalide antibiotic,” and beyond the concentration band.
- The exact identity of the suspending polymer because claim 1 only requires “polymeric suspending agent,” not the specific polymer chemistry (that enters in claim 2 and below).
High-sensitivity infringement levers
- Aqueous suspension: if the dosage form is non-aqueous, gelled without suspension characteristics, or a solution (fully dissolved), it may fall outside the suspension characterization.
- Concentration bands: staying outside 0.01% to 1.0% azalide and/or outside 0.1% to 10% suspending agent is a primary design-around axis.
- Topical ocular delivery: systemic administration would not meet the “eye” language. Anything intravitreal would be outside “topically applying” for most construction unless the formulation is applied topically to the ocular surface.
Dependent claims 2-10: Formulation chemistry narrows
Each dependent claim narrows the polymer identity, polymer composition, crosslinker identity, suspending agent concentration, particle distribution, and the azalide identity.
Which parts of US 6,239,113 are composition-limiting versus treatment-indication limiting?
Treatment-indication scope is wide; formulation scope is narrow
- The patent uses functional language for the indication: “treating an eye.”
- It does not restrict to a specific ocular disease, patient population, or dosing regimen duration in the claim language you provided.
- The formulation definition is the limiting set: polymer class, monomer composition, crosslinking agent, polymer concentration, particle distribution, and specific antibiotic form.
If a generic follows the same dosing route, does claim scope turn on the polymer chemistry?
Yes. If the competitor uses the same active and route but swaps the suspension polymer outside the claimed class (or uses a suspension polymer that is not “water-swellable water-insoluble crosslinked carboxy-vinyl polymer”), claim 2 and the narrower claims (3-8) become non-commuting.
What polymers are protected in claim 2 and what does “water-swellable water-insoluble crosslinked carboxy-vinyl polymer” cover?
Claim 2 polymer class
Claim 2 limits claim 1 by specifying the suspending agent as:
- “a water-swellable water-insoluble crosslinked carboxy-vinyl polymer.”
This is a functional-structural category:
- Carboxy-vinyl indicates polymers built from carboxyl-functional vinyl monomers, most commonly acrylic acid type monomers.
- Crosslinked excludes linear, non-crosslinked suspending agents.
- Water-swellable but water-insoluble describes polymers that swell in water but remain insoluble, matching typical muco-suspending/bioadhesive suspension polymer behavior.
Where claim 2 is broad
- It does not list a single polymer by name in claim 2.
- It does not explicitly require a specific crosslinker in claim 2 (that arrives in claim 4-5).
Where claim 2 is narrow
- The polymer must fit the combination “water-swellable,” “water-insoluble,” and “crosslinked carboxy-vinyl,” which can exclude:
- purely soluble polymers,
- non-crosslinked carboxy-vinyl thickeners,
- non-carboxy-vinyl suspension polymers,
- blends where the suspending agent is not itself that polymer.
How specifically are acrylic acid monomer content and crosslinking agent chemistry constrained (claims 3-5)?
Claim 3: Acrylic-rich crosslinked carboxy-vinyl polymer
Claim 3 requires:
- Polymer comprises at least 90% acrylic acid monomers.
- Crosslinking agent: 0.1% to 5%.
This is a key tightening move.
- Even within “carboxy-vinyl,” many copolymers include acrylate esters, methacrylates, or other comonomers; claim 3 demands at least 90% acrylic acid monomers.
- Crosslink density is constrained by the crosslinker percentage band.
Claim 4 and 5: Crosslinker must be difunctional and selected from a defined set
- Claim 4: “crosslinking agent comprises a difunctional crosslinking agent.”
- Claim 5: crosslinking agent selected from:
- divinyl glycol
- 2,3-dihydroxyhexa-1,5-diene
- 2,5-dimethyl-1,5-hexadiene
- divinylbenzene
- N,N-diallylacrylamide
- N,N-diallymethacrylamide
- or mixtures.
Practical impact
- A formulation using a different crosslinker chemistry not listed (or not mixtures of listed difunctional crosslinkers) avoids claim 5.
- If the polymer is an acrylic-acid-rich crosslinked polymer but uses a different difunctional crosslinker outside the enumerated set, it may avoid claim 5 while still possibly implicating claim 4 and claim 3 (depending on whether claim 4 requires difunctional only, which it does, and claim 3 only sets acrylic acid content and crosslinker percentage but not which crosslinker).
What is the claim coverage for polycarbophil and why does it matter (claim 6)?
Claim 6
“wherein said polymer comprises a polycarbophil.”
Polycarbophil is widely used as a suspending/retention polymer. This dependent claim makes the patent easier to assert against products using polycarbophil directly.
Practical effect
- If a competitor uses polycarbophil as the suspending agent, it is likely within claim 6 (subject to meeting the higher-level claim conditions: aqueous suspension, azalide concentration band, polymer class constraints in claim 2, acrylic-acid content in claim 3, etc.).
- If a competitor uses a different acrylic-acid crosslinked polymer but not polycarbophil, claim 6 is avoided but claims 2-3-4-5 could still be in play.
How does claim 7 constrain suspending agent loading, and how can that be used for design-around?
Claim 7
“polymeric suspending agent is contained in an amount of from about 0.5 to 1.2%.”
This narrows claim 1’s broad “0.1% to 10%” into a tighter window.
Design-around axis
- Keep the polymer amount below ~0.5% or above ~1.2% while maintaining other features may avoid claim 7 and the narrower dependent claims requiring claim 7.
- Claim 1 could still be implicated if the product remains within claim 1’s broader bands.
Does the patent require a specific particle size distribution (claim 8), and how strong is that narrowing?
Claim 8
“wherein said polymer has a monodisperse particle size distribution.”
This is a narrow and testable feature:
- Monodisperse distribution is a strong characterization. Many commercial polymers may have broader distributions.
Practical impact
- If the competitor’s polymer cannot be characterized as monodisperse by the relevant measurement standard, claim 8 may be avoidable.
- This claim also suggests the assignee sought to differentiate from typical suspension polymers with broader particle distributions.
What azalide antibiotics and salt forms are explicitly covered (claims 9-10)?
Claim 9
“azalide antibiotic comprises azithromycin.”
Claim 10
“azalide antibiotic comprises azithromycin dihydrate.”
This suggests:
- The patent’s strongest species-level coverage is with azithromycin and especially azithromycin dihydrate.
Practical impact
- If a competitor uses azithromycin but in a different solid form, claim 10 may not read.
- If a competitor uses a different azalide antibiotic (not azithromycin), claim 9-10 are avoided but claim 1’s broader “azalide antibiotic” can still apply if the active fits the azalide class and concentration.
How strong is infringement risk across a generic or follow-on formulation portfolio?
Risk map by claim layer (based on your claim text)
| Formulation feature |
Claim implicated if met |
Primary infringement driver |
| Aqueous polymeric suspension |
Claim 1 |
Vehicle type |
| Azalide antibiotic concentration 0.01%–1.0% |
Claim 1 |
Active loading band |
| Polymer suspending agent 0.1%–10% |
Claim 1 |
Polymer loading band |
| Polymer is water-swellable, water-insoluble, crosslinked carboxy-vinyl |
Claim 2 |
Polymer identity class |
| Polymer is ≥90% acrylic acid + 0.1%–5% crosslinker |
Claim 3 |
Polymer composition |
| Crosslinker is difunctional |
Claim 4 |
Crosslink class |
| Crosslinker is one of enumerated difunctional agents |
Claim 5 |
Exact crosslink identity |
| Polymer comprises polycarbophil |
Claim 6 |
Named polymer |
| Suspending agent loading 0.5%–1.2% |
Claim 7 |
Tight concentration window |
| Polymer particle distribution monodisperse |
Claim 8 |
Particle characterization |
| Azithromycin used |
Claim 9 |
Active identity |
| Azithromycin dihydrate used |
Claim 10 |
Salt/form identity |
Infringement likelihood
- Highest if a product:
- uses azithromycin dihydrate at 0.01%–1.0%,
- in an aqueous suspension,
- with a crosslinked acrylic acid-rich carboxy-vinyl polymer (polycarbophil particularly),
- with crosslinker within the enumerated set,
- at 0.5%–1.2% polymer loading,
- and demonstrates monodisperse particle size.
- Medium if it keeps claim 1’s formulation band and azalide class but uses a different polymer chemistry (likely avoids claims 2-8).
- Lower if it moves outside the active or polymer concentration bands, or uses a polymer not in the defined class.
What patent landscape considerations apply in the US around this kind of formulation claim?
How claim structure impacts enforcement
This patent is a classic formulation/process-of-use-at-application claim. For enforcement, the patent owner typically correlates:
- product composition (assayed % active and polymer),
- polymer chemistry (crosslinking type, monomer composition, whether it matches carboxy-vinyl),
- particle characterization (monodisperse),
- and dosage form/route (topical eye administration).
Where validity challenges typically concentrate (in litigation posture)
While the claim text you supplied does not include specification details, formulation patents like this commonly face:
- Obviousness over known ocular suspensions and known azalide ophthalmics,
- Indefiniteness around particle-size/monodisperse characterizations (if not anchored in the specification with measurement methods),
- Written description/enablement if the specification does not support the full breadth of polymer classes and the enumerated crosslinkers/species.
This matters because claims 2-8 contain specific chemistry and characterization. Those features can cut both ways: they can provide novelty but also create validity friction if support is thin.
Which design-around strategies are most aligned with the claim language?
Most direct: move outside the numeric bands
- Azalide concentration: avoid 0.01%–1.0%.
- Suspending agent: avoid 0.1%–10% for claim 1, or specifically avoid 0.5%–1.2% for claim 7.
Most structural: change the suspending polymer class
- Use a polymer that is not “water-swellable, water-insoluble, crosslinked carboxy-vinyl,” or not ≥90% acrylic acid.
- Use a crosslinked polymer with different crosslinker chemistry not in claim 5.
Most categorical: change the azalide form
- Use azithromycin rather than azithromycin dihydrate (to avoid claim 10).
- Use a non-azithromycin azalide (to avoid claim 9-10) while remaining in claim 1’s class constraints only if still “azalide antibiotic” is present.
Most characterization-based: avoid monodisperse particle distribution
- Employ polymers with standard broader particle size distributions.
- Avoid formulations that would be characterized as monodisperse under the relevant assessment.
Key takeaways
- Claim 1 provides the broadest coverage: topical ocular treatment via aqueous polymeric suspension containing an azalide antibiotic (0.01%–1.0%) and polymeric suspending agent (0.1%–10%).
- Dependent claims 2-8 narrow infringement risk to a specific polymer family: water-swellable, water-insoluble crosslinked carboxy-vinyl polymers, including ≥90% acrylic acid monomers, specific difunctional crosslinkers, and potentially polycarbophil, at 0.5%–1.2%, with monodisperse particle size.
- Dependent claims 9-10 concentrate the patent’s strongest active-species coverage on azithromycin and especially azithromycin dihydrate.
- The most effective design-arounds track the claims’ structure: change active concentration, polymer concentration, polymer identity/class, crosslinker identity, particle distribution, or salt form.
FAQs
-
Does US 6,239,113 require a specific ocular disease indication?
No. The claims you provided cover “treating an eye” without specifying a disease state in the claim language.
-
Can a formulation avoid the patent by changing polymer loading?
Yes. Claim 1 and claim 7 define distinct polymer concentration ranges; staying outside those numeric bands is a direct design-around route.
-
If a product uses azithromycin but not azithromycin dihydrate, which claims are avoided?
Claim 10 is avoided. Claim 9 can still be implicated if azithromycin is used.
-
How can a competitor avoid claims 2-5 without changing the active drug?
By selecting a suspending polymer that is not a water-swellable water-insoluble crosslinked carboxy-vinyl polymer, or by using an acrylic-acid-content and crosslinker chemistry outside the listed constraints.
-
Is “monodisperse particle size distribution” a meaningful narrowing feature?
Yes. Claim 8 adds a specific particle characterization requirement that can be used to distinguish from typical polymer particle distributions.
References
- United States Patent 6,239,113. “Process for treating an eye using an azalide antibiotic aqueous polymeric suspension.” (Claims provided in the prompt).
More… ↓
⤷ Start Trial
|
